Apricus Biosciences

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

The full company name is Aprinoia Therapeutics Inc.

Aprinoia Therapeutics has filed for a $50 million IPO to develop diagnostics and therapeutics for neurodegenerative diseases. The company's lead therapeutic candidate is in Phase 1a trials for Alzheimer's disease, Progressive Supranuclear Palsy, and Frontal Temporal Dementia. The global market for Alzheimer's disease treatment is expected to reach $17.4 billion by 2030, driving the company's growth potential.

News for Apricus Biosciences Stock (APRI)